Agenus Inc (FRA:AJ8)
€ 6.1 -0.25 (-3.94%) Market Cap: 278.07 Mil Enterprise Value: 291.19 Mil PE Ratio: 2.77 PB Ratio: 0 GF Score: 48/100

Q2 2025 Agenus Inc Earnings and Strategic Progress Call Transcript

Aug 27, 2025 / 08:00PM GMT
Release Date Price: €3.86 (-1.53%)
Stefanie Perna;Nacar
Agenus Inc - Chief Communications & Government Relations Officer

Good afternoon. My name is Stefanie Nacar, and I'm the Chief Communications Officer here at Agenus. Welcome to our webcast where we'll be discussing topics related to patient care, their experiences, their needs, and the work that's required to bring new options to those impacted by cancer, specifically colorectal cancer.

Before we begin, a quick reminder that today's discussion includes forward-looking statements. These are subject to risks and uncertainties that could make actual results different. Please be sure to check our website for our SEC filings.

Joining us today are distinguished leaders from industry and medicine, each bringing deep expertise and shared commitment to advancing patient care. From Agenus, we will be joined with our host for today, Dr. Garo Armen, our Chairman and CEO; as well as Dr. Richard Goldberg, our Chief Development Officer; and Jennifer Buell, Chairman, Executive Counsel at Agenus and President and CEO of MiNK Therapeutics will be joining us.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot